MIG - Press Review

 

2020

Alternativer Text

Süddeutsche Zeitung -

Express

„Süddeutsche Zeitung“ describes how BioNTech developed in a very short period the vaccine against Covid-19 and marks Michael Motschmann, General Partner of MIG AG, as one of the first investors of BioNTech.
Find out more
Alternativer Text

Financial Times -

FT People of the Year: BioNTech´s Ugur Sahin and Özlem Türeci

„Financial Times“ chooses BioNTech´s Ugur Sahin and Özlem Türeci as „People of the Year“. In a cover story MIG AG is described as a first investor and Matthias Kromayer, General Partner of MIG AG, is quoted.
Find out more
Alternativer Text

Techcrunch; goingpublic.de -

German Bionic raises $20 M led by Samsung for exoskeleton tech to supercharge human labor

„Techcrunch“ and other media report about a Series A-Financing of German Bionic Systems by MIG Fonds and other investors.
Find out more
Find out more
Alternativer Text

Bloomberg -

Bloomberg prognosis, 13. Dezember 2020, First Covid Vaccines´ Triumph Raises Hope for Cancer Fight

„Bloomberg prognosis“ explains how mRNA vaccines against Covid-19 raises hope in the fight against cancer, with quotes of Dr. Matthias Kromayer, General Partner of MIG AG.
Find out more
Alternativer Text

Tagesschau.de -

The couple behind the vaccine against Covid-19

„Tagesschau.de“ portrays Özlem Türeci and Ugur Sahin, the founder of MIG-portfolio company BioNTech, and quotes Michael Motschmann, General Partner of MIG AG.
Find out more
Alternativer Text

Handelsblatt -

From Biontech to Sputnik V

Dr. Matthias Kromayer, General Partner MIG AG, explains in a byline article for „Handelsblatt“ the differencies between the vaccines against Covid-19.
Find out more
Alternativer Text

Handelsblatt -

Start-up Konux gets a large order from Deutsche Bahn

„Handelsblatt“ reports about a large order of Deutsche Bahn to Konux, a MIG Portfolio company.
Find out more
Alternativer Text

Bayerische Staatszeitung -

Competition for the Super-Brain

„Bayerische Staatszeitung“ explains the development of Quantum Computing and reports about IQM, a MIG portfoliocompany.
Find out more
Alternativer Text

Frankfurter Allgemeine Zeitung -

Great Britain approves vaccine of Biontech and Pfizer against Covid 19

Like other media around the globe „FAZ“ reports about the first approval of Biontechs vaccine against Covid-19.
Find out more
Alternativer Text

Going Public; finanzwelt; tech.eu -

MIG Fonds invests in Innatera

Several Media report about investment of MIG Fonds in new portfolio company Innatera
Find out more
Find out more
Find out more
Alternativer Text

DIE ZEIT -

Application for admission of Corona vaccine submitted

„DIE ZEIT“ reports like many other media around the globe that MIG portfolio company BioNTech together with Pfizer submitted the application for admission of their Covid-19 vaccine at FDA .
Find out more
Alternativer Text

Frankfurter Allgemeine Sonntagszeitung -

The Billionaires behind the Vaccine

„FAS“ describes the engagement of BioNTech investors Andreas and Thomas Strüngmann and the role of Michael Motschmann, General Partner of MIG AG, financing the firm from Mainz.
Find out more
Alternativer Text

Süddeutsche Zeitung -

„Never in my career I met such a brilliant couple“

Michael Motschmann, General Partner of MIG AG, and Thomas Strüngmann explain in an interview with „Süddeutsche Zeitung“ their relationship as investors to BioNTech founders Prof. Dr. Ugur Sahin and Özlem Türeci.
Find out more
Alternativer Text

Handelsblatt -

Founder couple from Mainz develops vaccine against corona

In a title story „Handelsblatt“ portrays the founder of BioNTech und mentions the role of Michael Motschmann, General Partner of MIG AG, as first investor
Find out more
Alternativer Text

Handelsblatt -

IQM Hope in Quantum Computing

German business newspaper „Handelsblatt“ portrays MIG portfolio company IQM in a comprehensive article as hope of the European Quantum Computing Industry.
Find out more
Alternativer Text

The Times -

Vaccine milestone heralds „normal life“ by next spring

The breaking news about important steps toward a vaccine against Covid-19 causes, that newspapers around the world like „The Times“ report about the founders of BioNTech, a MIG portfolio company, on their frontpages.
Find out more
Alternativer Text

Gruenderszene, Venturebeat, tech.eu, Siliconcanal -

MIG Fonds lead financing round at IQM

Several media report a 36 Mio. Euro financing round at IQM Quantum Computing led by MIG Fonds.
Find out more
Find out more
Find out more
Find out more
Alternativer Text

Handelsblatt -

The Start-up of Gloria Seibert shaped the market in an early stage

„Handelsblatt“ explains in a comprehensive article the business model of Temedica and mentions MIG Fonds as investor.
Find out more
Alternativer Text

Reuters -

Behind Pfizer´s vaccine, an understated husband-and-wife „dream team"

Newswire „Reuters“ is portraying the couple behind BioNTech with quotes of Dr. Matthias Kromayer, General Partner MIG AG and for many years member of the supervisory board of BioNTech.
Find out more
Alternativer Text

Frankfurter Allgemeine Zeitung -

Corona-Vaccine of BioNTech effective in over 90 percent of cases

MIG-portfolio company BioNTech und partner Pfizer are announcing important improvements of their vaccine against Covid-19. Media around the world are reporting, among them „FAZ“.
Find out more
Alternativer Text

Handelsblatt -

If the digital consultant cares about your finance

reports about digital platforms in the finance industry and mentions wealthpilot, a MIG portfolio company.
Find out more
Alternativer Text

Frankfurter Allgemeine Zeitung -

IPolitics should stay away

In an interview with „FAZ“ Pfizer´s top executive Kathrin Jansen explains the cooperation with BioNTech, a MIG portfolio company, in the search for a vaccine against Covid-19
Find out more
Alternativer Text

Frankfurter Allgemeine Sonntagszeitung -

We get close to the target

Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, explains in an interview with „FAS“ the state of the art of the development of a vaccine against Covid-19.
Alternativer Text

Frankfurter Allgemeine Sonntagszeitung -

The Munich Start-up factory

An article in „FAS“ describes Technische Universität München (TUM) as excellent incubator of start-ups with quotes of Dr. Axel Thierauf, Venture Partner of MIG AG, about MIG portfolio companies with origin at TUM.
Alternativer Text

FAZ -

Golden Rain at Nasdaq

Quote of Dr. Matthias Kromayer in an article of „Börse Online“ about IPOs of Biontech companies at Nasdaq.
Alternativer Text

Life Science -

We were convinced early about the IPO plans of Immatics

Interview with Dr. Matthias Kromayer, General Partner MIG AG, about the IPO of our portfolio company Immatics. .
Find out more
Alternativer Text

Frankfurter Rundschau -

How a Start-up tries to avoid deadly infections in clinics

In a portray of MIG portfolio company GWA Hygiene GmbH newspaper „Frankfurter Rundschau“ explains the business model of the firm.
Find out more
Alternativer Text

Capital Heft Oktober -

Quantum Advantage

In a detailed story business magazine „Capital“ presents start-up IQM from Finland, a MIG portfolio company, as a leading european firm in the sector of Quantum Computing.
Alternativer Text

DIE WELT -

The new Spirit of equal Opportunities

German Newspaper „DIE WELT“ portrays Gloria Seibert, founder of MIG portfolio company Temedica.
Find out more
Alternativer Text

Der SPIEGEL -

Comeback of Plastics

The magazine „SPIEGEL“ points out the USP of MIG portfolio company APK in the recycling of plastics.
Alternativer Text

Handelsblatt -

Enormous demand

„Handelsblatt“ decribes the market for vaccines against Covid 19. The potential revenues in the first phase could be around 20 Billion US Dollar for firms like BioNTech, a portfolio company of MIG Fonds.
Find out more
Alternativer Text

Handelsblatt -

Biotech-Firm Immatics from Tübingen with Nasdaq Listing

„Handelsblatt.com“ reports about the Listing of MIG-portfolio company Immatics at New Yorks Nasdaq.
Find out more
Alternativer Text

FOCUS -

Biontech Vaccine: Good data creat hope in turnaround

„Focus“ and other media report about good results of BioNTech, a MIG portfolio company, in search of a vaccine against Covid-19.
Find out more
Alternativer Text

Manager Magazin -

Singapurs Funds Temasek invests in BioNTech

„Manager Magazin“ reports about a 250 million investment of Temasek in BioNTech, a MIG portfolio company.
Find out more
Alternativer Text

FAZ -

„It´s not a question to participate in a race“

„Süddeutschen Zeitung“ interviews Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, about the state of the art in developing a vaccine against Covid-19.
Find out more
Alternativer Text

FOCUS, Heft 23/2020 -

The next quantum leap

In an article in detail „Focus“ describes the state of the art of quantum computing in Europe and mentions MIG portfolio company IQM as a main player.
Alternativer Text

Focus -

Costs nothing, not destroyable

Magazine „Focus“ reports, how Airbus will beat Boing with new materials from Amsilk, a MIG-portfolio company.
Find out more
Alternativer Text

EU-Startups -

10 promising European deeptech startups leading us into the future

Platform „EU-Startups“ provides an overview of European „deeptech startups“ and highlights MIG-portfolio company IQM and the founder Dr. Jan Goetz.
Find out more
Alternativer Text

Manager Magazin -

Biontech expects first data til July in their development of a vaccine against Covid-19

Several media reports new steps of BioNTech, a MIG portfolio company, in search of a vaccine against the new Coronavirus.
Find out more
Alternativer Text

Gründerszene -

The start-up of this German build hardware for Quantumcomputers

„Gründerszene“ portrays Dr. Jan Goetz, CEO of IQM, a MIG portfolio company.
Find out more
Alternativer Text

Tagesschau, FAZ and other media -

First clinical study for a Corona-Vaccine in Germany approved

FAZ and other media report, that in Germany for the first time a clinical study got the approval to test a Corona-Vaccine. MIG-Portfolio company BioNTech is allowed to start tests of his vaccine with volunteers.
Find out more
Find out more
Alternativer Text

Handelsblatt -

Biontech and Pfizer are planning to produce millions of units of Corona-vaccine this year

Handelsblatt.com reports about the plans of BioNTech, a portfolio company of MIG Fonds, to develop and produce a vaccine against Covid-19 together with Pfizer.
Find out more
Alternativer Text

Manager Magazin -

Power-Paar against SARS-CoV-2

„Manager Magazin Online“ portrays Ugur Sahin and Özlem Türeci of BioNTech and acknowledge the role of MIG Fonds in founding and financing the firm.
Find out more
Alternativer Text

DIE ZEIT -

Saving the World

Weekly Magazine „DIE ZEIT“ reports about pharmaceutical companies searching for vaccines against SARS CoV-2 focusing on BioNTech, a MIG portfolio company.
Find out more
Alternativer Text

Going Public Media -

AFFiRiS erhält Patent für Parkinson-Medikament in China

„Going Public“ reports about progresses of MIG portfolio company AFFiRiS. The biotech firm, based in Vienna, got a patent in China and will start a clinical study (Parkinson) in the second half of the year.
Find out more
Alternativer Text

Financial Times -

Ugur Sahin : the immunologist racing to find a vaccine

„Financial Times“ portrays Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, who started the race to find the first vaccine against SARS CoV-2.
Find out more
Alternativer Text

transkript, Finanzwelt und andere -

Immatics is planning a listing on the Nasdaq

Several national and international media are reporting about the IPO-plans of MIG portfolio company Immatics in Q2. on the Nasdaq.
Find out more
Find out more
Find out more
Alternativer Text

Reuters, Handelsblatt, FAZ -

BioNTech in China alliance with Fosun over coronavirus vaccine candidate

Newswire „Reuters“ reports about a cooperation of BioNTech, a MIG portfolio company. Together with Fosun Pharmaceutical a vaccine against Covid-19 should be developed first in China.
Find out more
Find out more
Find out more
Alternativer Text

Life Science -

The IPO took BioNTech onto the international stage

„Life Sciences“ is interviewing Sierk Pötting, BioNTech SE, and Michael Motschmann, General Partner der MIG AG, about the success of BioNTech.
Mehr erfahren
Alternativer Text

Reuters -

Pfizer weighs working with BioNTech on potential coronavirus vaccine

Reuters reports, that Pfizer weighs working with MIG portfolio company BioNTech on a potential coronavirus vaccine.
Find out more
Alternativer Text

Finanzwelt -

Third Investment of MIG 16

Trade magazine „Finanzwelt“ reports about MIG Fonds newest investment in Neracare GmbH.
Find out more
Alternativer Text

OLED Brief -

Cynora introduces fluorescent blue emitter

Trade magazine „OLED-Brief“ reports about the first commercial OLED-product of Cynora, a MIG portfolio company.
Find out more
Alternativer Text

transkript -

Immatics closes second TCR-T-Billion Deal

Trade Magazine „transkript“ reports about a deal between immatics, a MIG porfolio company, and GlaxoSmithKline, which assures immatics milestone payments up to 1.1 Billion US Dollar.
Find out more
Alternativer Text

Finanzwelt -

„We align our portfolio along trends of the future“

„Finanzwelt“ reports about the year 2019 of MIG AG.
Find out more
Alternativer Text

Gründerszene -

„For me it would not be enough to sell shoes online“

Interview with Gloria Seibert, founder of Temedica, a new MIG portfolio company.
Find out more
Alternativer Text

transkript -

Advancecor achieves good data of Revacept

Trade magazine „transkript“ reports about a successful phase-II-study of biontech-firm AdvanceCOR, a MIG portfolio company.
Find out more
Alternativer Text

Wirtschaftswoche, Munich Start-up, Going Public Media, kma, Gründerszene -

Series B Funding of Temedica

Several media report about the 17 million Euro series-B-financing round of Temedica, which was led by MIG Fonds.
Find out more
Find out more
Find out more